ArticleProblemy endokrinologii2026
[Decreased blood oxytocin levels in obesity and in patients with newly diagnosed type 2 diabetes].
Article in Problemy endokrinologii, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity and type 2 diabetes (T2D) are common metabolic disorders. Oxytocin, a hypothalamic neuropeptide, has recently been recognized as a potential regulator of energy balance, appetite, and insulin sensitivity.
objectiveTo investigate the relationship between circulating oxytocin levels and metabolic parameters in individuals with obesity and newly diagnosed T2D. MATERIALS AND
methodsA total of 96 participants were enrolled, including 48 with normal glucose tolerance (NGT) and 48 with newly diagnosed T2D, each subdivided into normal-weight and obese groups. Anthropometric indices, glucose and lipid parameters, insulin, HbA1c, and high-sensitivity C-reactive protein were measured. Insulin resistance and β-cell function were assessed using the HOMA model.
resultsCirculating oxytocin levels were significantly lower in patients with T2D compared to NGT (p < 0.01), and in obese compared to normal-weight participants (p < 0.01). Low oxytocin was negatively correlated with BMI, waist circumference, HbA1c, glucose, insulin, lipids, and hs-CRP, but positively with β-cell function. Multiple regression analysis identified 2-hour glucose, BMI, and total cholesterol as independent predictors of oxytocin levels.
conclusionPatients with obesity and newly diagnosed T2D exhibit markedly reduced circulating oxytocin levels, associated with adverse metabolic profiles. These findings highlight oxytocin as a potential biomarker of early metabolic dysregulation and suggest new therapeutic perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.